reports
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History ...
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of Arrhythmias and Severe Disease Progression Despite Standard-of-Care Treatments Large Majority of PKP2-associated ARVC Patients Appear Eligible for TN-401 Gene Therapy Based on Low Rates of Preexisting Immunity to AAV9 Antib...
- Jonathan Moreland
- Jonathan Moreland
PBF PBF ENERGY INC. CLASS A
OMI OWENS & MINOR INC.
MOD MODINE MANUFACTURING COMPANY
CMC COMMERCIAL METALS COMPANY
ALDX ALDEYRA THERAPEUTICS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
JELD JELD-WEN HOLDING INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ZYME ZYMEWORKS INC.
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
LPI LAREDO PETROLEUM INC.
ASAN ASANA
PCVX VAXCYTE
UAN CVR PARTNERS LP
ZIP ZIPRECRUITER
PFBX INC.
BTMD PEOPLES FINANCIAL CORP. (MISSISSIPPI)
TEAF HAYMAKER ACQUISITION CORP III
GLSI ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
MEGI GREENWICH LIFESCIENCES INC
NMTC MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
SBGI NEUROONE MEDICAL TECHNOLOGIES CORP
CVI SINCLAIR INC
NYC CVR ENERGY
EU INC.
ECF NEW YORK CITY REIT
INC.
WISDOMTREE EURO DEBT FUND
ELLSWORTH FUND LTD
- Jonathan Moreland
XPL SOLITARIO ZINC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TTSH TILE SHOP HOLDINGS INC.
STAA STAAR SURGICAL CO.
SIG SIGNET JEWELERS LIMITED
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
RGP RESOURCES CONNECTION INC.
PBPB POTBELLY CORP.
PBF PBF ENERGY INC. CLASS A
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
CRM SALESFORCE.COM INC.
CMC COMMERCIAL METALS COMPANY
CDXS CODEXIS
APA.. APA CORP.
AB ALLIANCEBERNSTEIN HOLDING L.P.
FLWS 1-800-FLOWERS.COM CL A
GWRS GLOBAL WATER RESOURCES
JELD JELD-WEN HOLDING INC.
SVRA SAVARA
WGO WINNEBAGO INDUSTRIES INC.
PNBK PATRIOT NATIONAL BANCORP
FF FIRST MINING GOLD
DOMO DOMO INCORPORATED
FUND ROYCE FOCUS TRUST
FGBI INC.
VEL FIRST GUARANTY BANCSHARES
ZYME VELOCITY COMPOSITES
RZLT ZYMEWORKS INC.
WOOF REZOLUTE
UAN INC.
VSCO PETCO HEALTH AND WELLNESS
BTMD CVR PARTNERS LP
EWTX VICTORIA'S SECRET & CO
TEAF HAYMAKER ACQUISITION CORP III
JMSB EDGEWISE THERAPEUTICS INC
ERNA ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
GTE JOHN MARSHALL BANCORP INC
SSII ETERNA THERAPEUTICS INC.
CATX GRAN TIERRA ENERGY INC.
ADVM SS INNOVATIONS INTERNATIONAL INC
SUNS PERSPECTIVE THERAPEUTICS
BNTC INC.
FG ADVERUM BIOTECHNOLOGIES INC.
ALMU SUNRISE REALTY TRUST
FTLF BENITEC BIOPHARMA INC
ECF F AND G ANNUITIES AND LIFE
INC.
AELUMA
INC.
FITLIFE BRANDS INC.
ELLSWORTH FUND LTD
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair...
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth PALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. “We’re delighted to...
- Jonathan Moreland
XPL SOLITARIO ZINC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
STAA STAAR SURGICAL CO.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
MGPI MGP INGREDIENTS INC.
CRMD CORMEDIX INC.
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
WGO WINNEBAGO INDUSTRIES INC.
FGBI FIRST GUARANTY BANCSHARES
ZYME ZYMEWORKS INC.
PCB PACIFIC CITY FINANCIAL CORP
CTGO CONTANGO ORE INC.
BTMD HAYMAKER ACQUISITION CORP III
SSII SS INNOVATIONS INTERNATIONAL INC
ADVM ADVERUM BIOTECHNOLOGIES INC.
NYC NEW YORK CITY REIT
BNTC INC.
FTLF BENITEC BIOPHARMA INC
FITLIFE BRANDS INC.
Tenaya Therapeutics Announces Late Breaker Presentation of New Data fr...
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25 ...
- Jonathan Moreland
WYNN WYNN RESORTS LIMITED
ULTA ULTA BEAUTY INC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TITN TITAN MACHINERY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
OMCL OMNICELL INC.
MG MISTRAS GROUP
MEI METHODE ELECTRONICS INC.
MCHX MARCHEX INC. CL B
IMMR IMMERSION CORP.
HSC HARSCO CORPORATION
GOGO GOGO INC.
GCO GENESCO INC.
FGEN FIBROGEN INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
AHH ARMADA HOFFLER PROPERTIES INC.
ADBE ADOBE INC.
OPRX OPTIMIZERX CORP
QRHC QUEST RESOURCE HOLDING
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
ECC EAGLE POINT CREDIT CO INC
GCBC GREENE COUNTY BANCORP INC.
HI HILLENBRAND INC.
LIVE LIVE VENTURES
BV BRIGHTVIEW HOLDINGS
HFFG HF FOODS GROUP INC
TROX TRONOX HOLDINGS PLC
AEYE AUDIOEYE INC
ZYME ZYMEWORKS INC.
GRWG GROWGENERATION
PRLD PRELUDE THERAPEUTICS
FTHM FATHOM HOLDINGS
IMNM IMMUNOME
LYEL LYELL IMMUNOPHARMA INC
TOI ONCOLOGY INSTITUTE INC (THE)
HD HOME DEPOT
BTMD INC.
BLIN HAYMAKER ACQUISITION CORP III
BUKS BRIDGELINE DIGITAL INC
MODD BUTLER NATIONAL CORP
MLYS MODULAR MEDICAL INC
WEST MINERALYS THERAPEUTICS INC
SRFM WESTROCK COFFEE COMPANY LLC
GUTS SURF AIR MOBILITY INC.
ADVM FRACTYL HEALTH INC
AFCG ADVERUM BIOTECHNOLOGIES INC.
FG AFC GAMMA
EU INC.
F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
Xos, Inc. Reports Record-Breaking 2024 with Growing Unit Deliveries an...
Xos, Inc. Reports Record-Breaking 2024 with Growing Unit Deliveries and Highest-Ever Gross Profit Achieved $3.3 million of net cash provided by operating activities, and our first quarter of positive Free Cash Flow of $3.3 million Achieved positive gross margins of approximately 7% and approximately 18% non-GAAP gross margins, for the full year 2024 Exceeded 25% revenue growth year-over-year from 2023 to 2024 LOS ANGELES, March 28, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leading electric truck manufacturer and fleet services provider, today reported...
- Jonathan Moreland
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PBF PBF ENERGY INC. CLASS A
MCHX MARCHEX INC. CL B
CFFN CAPITOL FEDERAL FINANCIAL INC.
AHH ARMADA HOFFLER PROPERTIES INC.
LIVE LIVE VENTURES
ZYME ZYMEWORKS INC.
PCB PACIFIC CITY FINANCIAL CORP
PRLD PRELUDE THERAPEUTICS
UAN CVR PARTNERS LP
DRCT DIRECT DIGITAL HLDGS INC
SRFM SURF AIR MOBILITY INC.
ADVM ADVERUM BIOTECHNOLOGIES INC.
SUNS SUNRISE REALTY TRUST
AFCG AFC GAMMA
FG INC.
F AND G ANNUITIES AND LIFE
INC.
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 En...
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Development Plan to Evaluate TN-201 as a Potential Treatment for Patients with MYBPC3-associated Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that addres...
CPS Announces $65.0 Million Securitization of Residual Interests
CPS Announces $65.0 Million Securitization of Residual Interests LAS VEGAS, Nevada, March 20, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced the closing of a $65.0 million securitization of residual interests from previously issued securitizations. In the transaction, a qualified institutional buyer purchased $65.0 million of asset-backed notes secured by an 80% interest in a CPS majority owned affiliate (“MOA”) that owns the residual interests in five CPS securitizations issued from October 2023 through September 2024. ...
MacroGenics Provides Update on Corporate Progress and 2024 Financial R...
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the sec...
Tenaya Therapeutics Announces Late Breaker and New Data Presentations ...
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that new clinical and disease burden data pert...
Kalaris Announces Closing of Merger with AlloVir
Kalaris Announces Closing of Merger with AlloVir Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina Currently enrolling nAMD patients in a Phase 1 trial, with initial data from Part 1 of the trial expected in the second half of 2025 Post-transaction cash of approximately $100 million expected to fund operations into the fourth quarter of 2026 Shares expected to trade on Nasdaq under “KLRS”, effective March 19, 2025 ...
Atlassian Achieves FedRAMP(R) Moderate Authorization for Atlassian Gov...
TEAM Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced that Atlassian Government Cloud has received Federal Risk and Authorization Management Program (FedRAMP) authorization at the Moderate level. FedRAMP is a U.S. government program that promotes the adoption of cloud technologies across the federal government by providing a standardized approach to validating security and risk controls for cloud-based products and services. With this authorization, U.S. federal, state, and local...
- Jonathan Moreland
THFF FIRST FINANCIAL CORP. (INDIANA)
ORRF ORRSTOWN FINANCIAL SERVICES INC.
MPC MARATHON PETROLEUM CORPORATION
MGPI MGP INGREDIENTS INC.
DLY LYONDELLBASELL INDUSTRIES NV
FFIN FIRST FINANCIAL BANKSHARES INC
CIM CHIMERA INVESTMENT CORPORATION
CE CELANESE CORPORATION
TREE LENDINGTREE INC.
BWFG BANKWELL FINANCIAL GROUP
SNBR SLEEP NUMBER CORPORATION
TCPC BLACKROCK TCP CAPITAL CORP.
NFE NEW FORTRESS ENERGY
ZYME ZYMEWORKS INC.
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
UAN CVR PARTNERS LP
CMTG CLAROS MORTGAGE TRUST
ECAT INC.
EBC BLACKROCK ESG CAP ALLOCATION TR
MEGI EASTERN BANKSHARES INC
NE MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
SMRT NOBLE CORP (NEW)
SRBK SMARTRENT INC
NBBK SR BANCORP INC
BHRB NB BANCORP INC.
MXF BURKE HERBERT FINANCIAL SERVICES CORP
EVM THE MEXICO FUND
VG INC.
EATON VANCE INSD CALIF MUN BD FD
VENTURE GLOBAL INC.
Kalaris and AlloVir Announce Stockholder Approval of Merger
Kalaris and AlloVir Announce Stockholder Approval of Merger Combined company expected to trade on Nasdaq under “KLRS” after closing PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12, 2025. The AlloVir stockholders ...
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financia...
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at the American College of Cardiology Meeting Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 Recent $48.9 Million Financing Extends Cash Runway into mid-2026 SOUTH SAN FR...
- Jonathan Moreland
PEB PEBBLEBROOK HOTEL TRUST
PBF PBF ENERGY INC. CLASS A
MTDR MATADOR RESOURCES COMPANY
MPC MARATHON PETROLEUM CORPORATION
LTRX LANTRONIX INC.
FRPT FRESHPET INC
EIX EDISON INTERNATIONAL
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
CMCO COLUMBUS MCKINNON CORPORATION
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
FRAF FRANKLIN FINANCIAL SERVICES CO.
ELAN ELANCO ANIMAL HEALTH INC.
ABCL ABCELLERA BIOLOGICS
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
JANX JANUX THERAPEUTICS INC
TNYA TENAYA THERAPEUTICS INC
IE IVANHOE ELECTRIC INC
ECAT BLACKROCK ESG CAP ALLOCATION TR
ELTX ANGION BIOMEDICA CORP
CVI CVR ENERGY
GAM INC.
GENERAL DE ALQUILER DE MAQUINARIA
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.